TORONTO and DALLAS , Sept. 8, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV:Â PINK) (OTCQX:Â PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that it has joined the American Society of Breast Surgeons' ("ASBrS") Industry Relations Council ("IRC"). ...

Summary of Healthcare Policy Playbook 2.0 Industry Overview - **Industry**: Healthcare - **Region**: North America - **Event**: MS Global Healthcare Conference (Sept. 8-10, 2025) [1] Key Takeaways US Public Policy Insights - **Tariffs on Pharmaceuticals**: Anticipation of sectoral tariffs on pharmaceuticals, with uncertain timing and severity. The Section 232 review is expected to conclude soon, initiated in April [3][17]. - **Regulatory Changes**: Proposed unilateral policy changes may lack enforceability, indicating that substantial changes typically require Congressional action. The Most-Favored-Nation (MFN) drug pricing policy is likely to face delays [3][18]. - **Medicaid Cuts**: The One Big Beautiful Bill Act includes delayed Medicaid cuts, primarily through work requirement changes, aligning with expectations. This could lead to approximately 10 million individuals losing access to federal health insurance by 2034 [3][22][32]. - **Bipartisan Healthcare Package**: Potential for Congress to pass a bipartisan healthcare package addressing the expiration of ACA subsidies, possibly retroactive to 2026 [3][24]. Implications Across Healthcare Sectors - **Managed Care / Pharmaceutical Services**: Managed Care Organizations (MCOs) may benefit from increased support for Medicare Advantage (MA) under the current administration, despite significant Medicaid funding cuts. The 2026 MA Final Rate Notice showed a surprising increase of +5.75% [4][27]. - **Biopharma**: Investor sentiment remains negative due to uncertainties regarding tariffs and MFN pricing. Companies that can drive growth through the end of the decade are favored, including ABBV, LLY, GILD, and REGN [9][10]. - **SMID-Cap Biotech**: Concerns over FDA personnel changes and headcount reductions are significant for investors. However, the impact on drug review timelines has been less severe than anticipated [9][11]. - **Medical Technology**: Tariffs are pressuring margins for companies exposed to them, with potential delays in FDA approval timelines due to HHS layoffs. Companies with manufacturing in tariff-affected regions may face margin pressures [9][12]. - **Life Science Tools & Diagnostics**: The policy landscape remains uncertain, with tariffs and NIH funding uncertainties weighing on sentiment. Preference is given to Precision Oncology and diversified tools as safer investments [9][12]. Regulatory and Legislative Developments - **Medicaid Budget Cuts**: The OBBBA includes significant cuts to Medicaid, with work requirements expected to decrease enrollment by approximately 5 million by 2034 [22][32]. - **PBM Reform**: Ongoing bipartisan discussions around PBM reform, with recent state-level initiatives and potential federal legislation still in flux [33][36]. - **Audit and Compliance**: The administration plans to expedite MA contract audits, which could improve transparency but also introduce uncertainty for MCOs [28][29]. Market Sentiment and Stock Implications - **Healthcare Services**: Stocks positively impacted by favorable Medicare policies include UNH, ELV, HUM, and CVS, while those negatively affected by Medicaid cuts include ELV, UNH, CNC, and MOH [13][29]. - **Drug Distributors**: Generally insulated from major changes in drug prices, with a shift towards fee-for-service models providing stability [41]. Additional Insights - **Tariff Management**: Current tariffs have been manageable for the services group, with companies implementing mitigation strategies [39]. - **Most-Favored Nations Policy**: The MFN drug pricing initiative remains uncertain, with drug distributors expressing that Congressional action is necessary for implementation [40][42]. This summary encapsulates the key points from the healthcare policy playbook, highlighting the evolving regulatory landscape and its implications for various sectors within the healthcare industry.

Summary of Key Points from the HSBC China Healthcare Conference Industry Overview - The industrial supply chain for innovative drugs in China is benefiting from domestic policy support and strong business development demand from global multinationals [4][5] - Leading pharmaceutical companies are well-positioned with diversified pipelines and abundant clinical trial resources in China [4] - Medtech companies faced challenges in the first half of 2025 but are expected to recover due to improved domestic demand and readiness for global supply-chain changes [4] - CXOs (pharma outsourcing services) are showing signs of recovery with higher utilization rates and solid backlogs, indicating that the worst is behind them [4] - Hospitals and pharmacies are still facing challenges due to domestic demand fluctuations and changing consumer behavior [4] Key Takeaways from the Conference - China has made significant advancements in healthcare over the past 10-15 years, particularly in innovative drug development and participation in global clinical trials [5] - Large pharmaceutical companies are focusing on internal R&D and business development as strategies to capitalize on opportunities in the Chinese market [5] - Despite uncertainties related to US drug pricing and regulatory changes, there is a trend towards developing best-in-class drugs at lower costs, with Chinese companies positioned to benefit global patients [5] - The innovative drug sector is expected to be a new chapter in China's pharmaceutical story, integrating more into the global healthcare ecosystem [5] Investor Sentiment and Market Trends - Investor sentiment towards China healthcare is positive, with a focus on drug innovation, although concerns remain regarding geopolitical impacts on CXOs [6] - Leading pharmaceutical and biotech companies are favored by investors due to new inflows from ETFs and increasing healthcare positioning [6] - Medtech is anticipated to be a strong sector in 2026 as signs of growth recovery in the domestic market are awaited [6] Stock Recommendations - Preferred stocks include Hansoh Pharma (3692 HK), Wuxi XDC (2268 HK), and Snibe (300832 CH), all rated as Buy [6][8] - Hansoh Pharma has a target price of HKD 47.00, implying a 26% upside from its current price of HKD 37.18 [15] - Wuxi XDC has a target price of HKD 75.00, indicating an 11.9% upside from its current price of HKD 67.00 [15] - Snibe has a target price of RMB 76.00, suggesting a 17.2% upside from its current price of RMB 64.82 [15] Financial Performance Insights - Global healthcare funding has shown recovery, with 1H25 growth at 18% year-over-year [10] - CXOs and biopharmaceuticals have led A-share performance in the past three months, while pharmacies and medical services have lagged [10][12] - The performance of various healthcare subsectors indicates a strong recovery in CXOs and biopharma, contrasting with the struggles of hospitals and distributors [11][12] Risks and Challenges - Potential risks include slower-than-expected sales ramp-up of new drugs, R&D progress delays, and impacts from anti-graft policies [15] - Biotech funding volatility and global competition could affect Wuxi XDC's growth [15] - Snibe faces risks from reduced IVD testing volumes and potential price cuts due to regulatory changes [15] This summary encapsulates the key insights and recommendations from the HSBC China Healthcare Conference, highlighting the positive outlook for the innovative drug sector while acknowledging the challenges and risks that remain.

Summary of Mindray's Asia Leaders Conference 2025 Company Overview - **Company**: Mindray (300760.SZ) - **Industry**: Medical Technology (Medtech) - **Market Cap**: Rmb289.6 billion / $40.5 billion - **Enterprise Value**: Rmb270.3 billion / $37.8 billion - **Revenue Contribution**: 55% of 2024 revenue from China [5][7] Key Insights from the Conference Revenue and Growth Projections - Mindray maintains guidance for revenue growth to turn positive by 3Q25, but bottom line growth may remain negative due to Gross Profit Margin (GPM) pressure [1][5] - China sales channel destocking is expected to be completed by the end of this year, with no guidance on China growth for 2026 due to policy uncertainties [1][4] - Overseas growth is projected to maintain a double-digit rate, estimated at around 15%-20% CAGR from emerging markets over the next several years [1][4] GPM and Pricing Pressure - The company has experienced a GPM decrease of approximately 5% in China and anticipates further pressure in the second half of 2025 [4][5] - Pricing pressure is expected to persist until 2026 due to the implementation of Value-Based Procurement (VBP) and new hospital testing price guidelines [4][5] Competitive Landscape - Intense price competition is noted within the medical equipment sector, particularly for low-end products [4][5] - Many distributors are currently achieving only single-digit net margins, leading to a faster exit of smaller IVD companies from the market [4][5] Investment Thesis - Mindray is positioned as a leading medtech device manufacturer in China, with strong growth drivers including healthcare infrastructure development and domestic substitution [5][6] - The company is trading below its 5-year average forward P/E, primarily due to policy risks, but is expected to maintain its market leader position [5][6] Price Target and Risks - The 12-month target price is set at Rmb296, indicating an upside potential of 23.9% from the current price of Rmb238.81 [7] - Key downside risks include further impacts from VBP, slower penetration into top-tier hospitals in China, challenges in entering North American and European markets, patent-related lawsuits, and unexpected changes in trade policies [6][7] Additional Considerations - The company is focusing on maintaining market share in hospital procurement rather than historical profitability levels [4][5] - The IVD industry outlook suggests a normalization of volume decreases due to DRG/DIP reforms by 2026, following a low base in 2025 [4][5] This summary encapsulates the critical points discussed during Mindray's Asia Leaders Conference, highlighting the company's strategic focus, market challenges, and growth opportunities within the medtech industry.

Core Viewpoint - BioStem Technologies, Inc. is showcasing its innovative placental-derived products for chronic wound care at the Symposium for Advanced Wound Care (SAWC) Fall meeting, emphasizing collaboration with Venture Medical, LLC to enhance patient care and streamline treatment processes [1][2]. Company Overview - BioStem Technologies focuses on the development, manufacturing, and commercialization of placental-derived products aimed at advanced wound care [1][11]. - The company utilizes its proprietary BioREtain processing method, which preserves the natural properties of perinatal tissue, ensuring the integrity of amniotic tissue components critical for wound treatment [8][11]. Product Highlights - Key products include AmnioWrap2® and Vendaje AC®, which are exclusively available through Venture Medical [3]. - The BioStem-Venture collaboration aims to provide a superior allograft platform that meets the needs of both patients and healthcare providers [3]. Event Details - The SAWC Fall meeting is taking place from September 3-6 in Las Vegas, NV, serving as a significant educational forum for healthcare professionals focused on chronic wound care [1]. - A sponsored breakfast symposium titled "Navigating the Future of Wound Care" will feature discussions on clinical evidence and best practices in wound care management [4]. Research Contributions - BioStem has three clinical and scientific posters accepted for display at the symposium, contributing to the discourse on chronic wound care [5][10]. - Research topics include comparisons of processing methods for placental tissue allografts and sterilization methods for dehydrated birth tissue [6][10]. Strategic Partnership - The collaboration with Venture Medical enhances the logistics of managing patients requiring skin substitutes for chronic wound treatment, showcasing a combined value proposition [2][3][13].

Summary of TriSalus Life Sciences Conference Call Company Overview - **Company**: TriSalus Life Sciences (TLSI) - **Industry**: MedTech, Life Science Tools, and Diagnostics - **Technology**: Microcatheter technology designed to enhance drug delivery to solid tumors, particularly in the liver and other areas Key Points and Arguments 1. **Technology and Market Opportunity**: - TriSalus's technology addresses the challenge of delivering drugs to solid tumors, where less than 1% of drugs can penetrate due to high internal pressure [3][4] - The company has expanded its market opportunity from approximately $400 million to nearly $2.5 billion, primarily targeting liver metastases and primary liver cancer [8] 2. **Growth and Financial Performance**: - The company reported a 50% growth in the first half of 2025 compared to the first half of 2024, with a 22% sequential growth from Q1 to Q2 [9] - New product launches, including a more trackable version of their technology and a product for uterine fibroids, are expected to drive growth [10] 3. **Reimbursement Strategy**: - TriSalus has developed its own embolization procedural code for Pressure-Enabled Drug Delivery, which is favorable for hospitals and saves over $8,000 per patient for CMS [12] - The reimbursement model is designed to be cash positive for hospitals, enhancing the adoption of their technology [12] 4. **Sales and Market Penetration**: - The company focuses on existing accounts for growth, with a strategy to expand usage among multiple physicians within hospitals [13][14] - TriSalus targets high-volume interventional radiology accounts, with 57 out of 100 identified accounts performing well [21] 5. **Education and Adoption Challenges**: - The primary barrier to adoption is the lack of education regarding intratumoral pressure and the tumor microenvironment among physicians [22][25] - The company is focused on training and registry studies to support the adoption of their technology [26][30] 6. **Future Developments**: - Upcoming milestones include data releases on various applications, including uterine fibroids and genicular artery procedures [36] - The company is also looking to partner for the advancement of nelitolimod, targeting liver and pancreatic indications [32][33] 7. **Financial Outlook**: - The company aims for near-term cash flow breakeven, with opportunities for cost savings and efficiency improvements [34][35] - The focus remains on scaling sales and marketing efforts while leveraging clinical evidence from registry studies to enhance market presence [35] Additional Important Content - The technology allows for a non-invasive procedure for thyroid embolization, which avoids risks associated with traditional methods [28][29] - The company is committed to educating physicians about the new methodologies and ensuring proper training for interventional radiologists [25][30]

Company Overview - OrthoPediatrics Corp. focuses exclusively on pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions, currently marketing over 80 products across three major categories: trauma and deformity, scoliosis, and sports medicine [5] - MY01, founded in 2019, specializes in medical technology aimed at transforming the diagnosis of limb perfusion injuries through its Continuous Perfusion Sensing Technology™ (CPST™) Platform, which provides real-time data to support better decision-making in trauma care [4] Partnership Announcement - OrthoPediatrics has announced a new distribution partnership with MY01 to expand access to the CPST™ Platform for pediatric patients, particularly those at risk for acute compartment syndrome [1][3] - The partnership aims to ensure clinicians have the necessary tools and training to reduce variability in care and optimize outcomes for pediatric patients, thereby avoiding unnecessary surgeries and complications [3] Industry Context - Acute compartment syndrome is a critical emergency condition that primarily affects children with specific orthopedic injuries, making timely diagnosis essential [2] - The collaboration between OrthoPediatrics and MY01 is positioned to address the challenges in diagnosing acute compartment syndrome in pediatric patients, who may have difficulty communicating their pain [2][3]

Company Overview - SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [3] - The company's first commercial product, QUELIMMUNE, is based on its patented Selective Cytopheretic Device (SCD) technology and was approved by the FDA in 2024 [3] - QUELIMMUNE is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [3] Product and Technology - The Selective Cytopheretic Device (SCD) therapy has received Breakthrough Device Designation for six therapeutic indications from the FDA, which may facilitate a faster approval process and better reimbursement dynamics [3] - SeaStar Medical is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a condition affecting over 200,000 adults in the US annually [3] Upcoming Events - SeaStar Medical will participate in the HC Wainwright 27th Annual Global Investment Conference, with a presentation scheduled for September 5, 2025, at 7:00 am Eastern Time [1][2]

Core Insights - The company has made significant progress since becoming independent, particularly in research and development investments [1] - A series of product launches are anticipated in 2026, which are expected to transform the company over time [1] - The company has successfully focused on improving controllable margins [1]

Group 1 - The company reported strong top-line growth of 6% in the third quarter, particularly driven by the pharma and CAM sectors [1][2] - The revenue guidance for 2025 has been increased, indicating broad-based growth with significant contributions from pharma, CAM, and CDMO [2] - Key innovations such as Infinity III, Pro iQ Plus on the LC/MS side, and 8850 innovations have resonated well in the market, contributing to the growth [2] Group 2 - The service business achieved customer satisfaction scores greater than 90%, highlighting the importance of customer intimacy in the current environment [2] - The pharma sector showed strong performance, with small molecule QA/QC leading the growth [2]